Renal Transitional Cell Carcinoma Questions & Answers

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan. 72 (1):7-33. [QxMD MEDLINE Link]. [Full Text].

2. De Broe ME. Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. Kidney Int. 2012 Mar. 81 (6):513-5. [QxMD MEDLINE Link].

3. Grollman AP, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A. 2007 Jul 17. 104(29):12129-34. [QxMD MEDLINE Link].

4. Colin P, Koenig P, Ouzzane A, et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int. 2009 Nov. 104(10):1436-40. [QxMD MEDLINE Link].

5. American Cancer Society. Cancer Facts & Figures 2022. Available at https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf. Accessed: June 12, 2022.

6. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009 Mar 15. 115(6):1224-33. [QxMD MEDLINE Link].

7. Park J, Ha SH, Min GE, et al. The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival. J Urol. 2009 Sep. 182(3):894-9. [QxMD MEDLINE Link].

8. Novara G, De Marco V, Dalpiaz O, et al. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from three European centers. Int J Urol. 2009 Feb. 16(2):187-91. [QxMD MEDLINE Link].

9. Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, et al. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol. 2017 Feb. 71 (2):281-289. [QxMD MEDLINE Link].

10. Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013 Apr. 63 (4):717-23. [QxMD MEDLINE Link]. [Full Text].

11. Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, et al. Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. J Urol. 2016 Feb. 195 (2):277-82. [QxMD MEDLINE Link].

12. Todenhofer T, Hennenlotter J, Esser M, et al. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma. Cancer Cytopathol. 2012 Nov 21. [QxMD MEDLINE Link].

13. Vikram R, Sandler CM, Ng CS. Imaging and staging of transitional cell carcinoma: part 2, upper urinary tract. AJR Am J Roentgenol. 2009 Jun. 192(6):1488-93. [QxMD MEDLINE Link].

14. Jeong YB, Kim HJ. Is It Transitional Cell Carcinoma or Renal Cell Carcinoma on Computed Tomography Image?. Urology. 2011 Dec 21. [QxMD MEDLINE Link].

15. Rastinehad AR, Ost MC, Vanderbrink BA, et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guerin therapy?. Urology. 2009 Jan. 73(1):27-31. [QxMD MEDLINE Link].

16. Demery ME, Thezenas S, Pouessel D, Culine S. Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function. Anticancer Drugs. 2012 Feb. 23(2):143-8. [QxMD MEDLINE Link].

17. Tully CM, Apolo AB, Zabor EC, Regazzi AM, Ostrovnaya I, Furberg HF, et al. The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. Cancer. 2016 Mar 1. 122 (5):712-21. [QxMD MEDLINE Link].

18. Giannatempo P, Pond GR, Sonpavde G, Raggi D, Naik G, Galsky MD, et al. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Apr. 69 (4):624-33. [QxMD MEDLINE Link].

19. Di Lorenzo G, Buonerba C, Bellelli T, Romano C, Montanaro V, Ferro M, et al. Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study. Medicine (Baltimore). 2015 Dec. 94 (51):e2297. [QxMD MEDLINE Link]. [Full Text].

20. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7. 387 (10031):1909-20. [QxMD MEDLINE Link].

21. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2016 Dec 7. [QxMD MEDLINE Link].

22. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Jan 25. [QxMD MEDLINE Link].

23. FDA approves avelumab for urothelial carcinoma maintenance treatment. FDA.gov. Available at https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment#:~:text=On%20June%2030%2C%202020%2C%20the,%2Dline%20platinum%2Dcontaining%20chemotherapy.. July 1, 2020; Accessed: June 12, 2022.

24. FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer). Merck.com. Available at https://www.merck.com/news/fda-approves-updated-indication-for-mercks-keytruda-pembrolizumab-for-treatment-of-certain-patients-with-urothelial-carcinoma-bladder-cancer/. August 31, 2021; Accessed: June 12, 2022.

25. Zibelman M, Ramamurthy C, Plimack ER. Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. Urol Oncol. 2016 Dec. 34 (12):538-547. [QxMD MEDLINE Link].

26. Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019 Jul 25. 381 (4):338-348. [QxMD MEDLINE Link].

27. Pak RW, Moskowitz EJ, Bagley DH. What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival. J Endourol. 2009 Mar. 23(3):341-6. [QxMD MEDLINE Link].

28. Straub J, Strittmatter F, Karl A, Stief CG, Tritschler S. Ureterorenoscopic biopsy and urinary cytology according to the 2004 WHO classification underestimate tumor grading in upper urinary tract urothelial carcinoma. Urol Oncol. 2012 Jan 31. [QxMD MEDLINE Link].

29. Hsueh TY, Huang YH, Chiu AW, et al. A comparison of the clinical outcome between open and hand-assisted laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma. BJU Int. 2004 Oct. 94(6):798-801.

30. Kawauchi A, Fujito A, Ukimura O, et al. Hand assisted retroperitoneoscopic nephroureterectomy: comparison with the open procedure. J Urol. 2003 Mar. 169(3):890-4; discussion 894. [QxMD MEDLINE Link].

31. Ong AM, Bhayani SB, Pavlovich CP. Trocar site recurrence after laparoscopic nephroureterectomy. J Urol. 2003 Oct. 170(4 Pt 1):1301. [QxMD MEDLINE Link].

32. [Guideline] Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology guidelines on Upper Tract Urothelial Carcinomas. 2022 Update. Available at https://uroweb.org/guidelines/upper-urinary-tract-urothelial-cell-carcinoma. Accessed: June 12, 2022.

33. [Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer Version 2.2022. Available at https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. May 20, 2022; Accessed: June 12, 2022.

Bagi RP Jana, MD, MBA, MHA, FACP Professor of Cancer Medicine, MD Anderson Cancer Center; Professor of Medicine, University of Texas Medical Branch at Galveston

Bagi RP Jana, MD, MBA, MHA, FACP is a member of the following medical societies: American Cancer Society, American Medical Association, American Society of Clinical Oncology, SWOG

Disclosure: Nothing to disclose.

Kush Sachdeva, MD Southern Oncology and Hematology Associates, Inspira Health Network

Disclosure: Nothing to disclose.

E Jason Abel, MD Associate Professor of Urologic Oncology, Department of Urology, Associate Professor of Radiology (Affiliate Appointment), Department of Radiology, University of Wisconsin School of Medicine and Public Health; Attending Urologist, William S Middleton Memorial Veterans Hospital

E Jason Abel, MD is a member of the following medical societies: American Medical Association, American Society of Clinical Oncology, American Urological Association, Harris County Medical Society, Kidney Cancer Association, Society for Basic Urologic Research, Society of Urologic Oncology, Texas Medical Association

Disclosure: Nothing to disclose.

Neeraj Agarwal, MD Associate Professor of Medicine, Director of Genitourinary Oncology, Associate Director of Clinical Trials Office, Co-Leader of Urologic Oncology Multidisciplinary Program, Division of Medical Oncology, Huntsman Cancer Institute, University of Utah School of Medicine

Neeraj Agarwal, MD is a member of the following medical societies: American Association for Cancer Research, American Society of Clinical Oncology, SWOG

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Pfizer, Exelixis, Eisai, Novartis, Merck, Argos<br/>Received research grant from: Pfizer, Bayer.

Georgi Guruli, MD, PhD Consulting Staff, Department of Surgery, Division of Urology, University Hospital; Assistant Professor, Department of Surgery, Division of Urology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Disclosure: Nothing to disclose.

Wendy Hu, MD Consulting Staff, Department of Hematology/Oncology and Bone Marrow Transplantation, Huntington Memorial Medical Center

Wendy Hu, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Blood and Marrow Transplantation, American Society of Hematology, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Badrinath R Konety, MD Associate Professor, Department of Urology, University of California, San Francisco, School of Medicine

Disclosure: Nothing to disclose.

Michael Perry, MD, MS, MACP Nellie B Smith Chair of Oncology Emeritus, Director, Division of Hematology and Medical Oncology, Deputy Director, Ellis Fischel Cancer Center, University of Missouri-Columbia School of Medicine

Michael Perry, MD, MS, MACP is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, International Association for the Study of Lung Cancer, and Missouri State Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

• Print this section
• Print the entire contents of
• Print the entire contents of article